Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-2102 for critical lower limb ischemia: randomized double-blind phase II trial
CTR20260487Phase 2Active
- Sponsor
- Neurophth
- Start
- Mar 2026
- Countries
- 1
01
Overview
A Phase 2 trial of RGL-2102 in arteriosclerosis obliterans, Buerger disease (TAO), sponsored by Neurophth. Started Mar 2026; status: active.
02
Drugs
RGL-2102
03
Conditions
arteriosclerosis obliteransBuerger disease (TAO)
Beyond the preview
Go deeper on CTR20260487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260487.